Latest News and Press Releases

PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of the DurAVR® bIomimetic valve designed for physioloGic flow compared to CoMmercial TAVR devices MINNEAPOLIS and...

Anteris DurAVR THV demonstrates favorable hemodynamics in small annuli patients with no valve related mortality at one year - TCT oral presentation

Anteris Technologies Announces First Patients Treated in the DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed...

Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Anteris Announces Results for the First Quarter of 2025